MedicaidPrior AuthMedium impact
Libtayo® (cemiplimab-rwlc) (New)
Humana·IN · Oncology, Dermatology·Medicaid
Effective date
Feb 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Indiana Medicaid has established a new prior authorization policy for Libtayo (cemiplimab-rwlc), an IV cancer treatment drug. The policy covers four specific cancer indications including skin cancers and lung cancer, with 6-month approval durations and specific clinical criteria that must be met.
Action Required
Before February 1, 2026: Billing team must implement prior authorization requirements for Libtayo (cemiplimab-rwlc) IV infusions for Indiana Medicaid patients. Update billing system to flag cases requiring prior auth for cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer treatments. Train staff to verify clinical criteria are met before treatment administration. Claims without prior authorization will be denied.